Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROGRESS: INCB000928 in fibrodysplasia ossificans progressiva
2023-504129-38-00Phase 2Authorised
- Sponsor
- Incyte
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial in fibrodysplasia ossificans progressiva (FOP) comparing INCB000928 with Placebo (2 arms). Primary endpoint: Occurrence of new heterotopic ossification lesions. Planned start Mar 2022; status: authorised.
02
Drugs
zilurgisertib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2023-504129-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504129-38-00.